



Current Agreements

Dealdoc

Asset purchase agreement for 31 generic drug products

ANI Pharmaceuticals
Teva Pharmaceutical Industries

Dec 26 2013

Asset purchase agreement for 31 generic drug products

Companies:	ANI Pharmaceuticals Teva Pharmaceutical Industries
Announcement date:	Dec 26 2013
Deal value, US\$m:	12.5 : sum of cash payment

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Dec 26 2013 Bigbiotech Bigpharma Biotech Generic pharma Pharmaceutical Product
Industry sectors:	
Asset type:	Drug delivery » Oral delivery » Rapid release Drug delivery » Oral delivery » Delayed release Small molecules
Technology types:	
Deal components:	Asset purchase
Stages of development:	Marketed

Financials

Deal value, US\$m:	12.5 : sum of cash payment
Upfront, US\$m:	12.5 : initial cash payment
Royalty rates, %:	n/d : percentage of future gross profits from product sales

Termsheet

ANI Pharmaceuticals has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for \$12.5 million in cash and a percentage of future gross profits from product sales.

The acquisition includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products.

ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014.

Press Release

ANI Pharmaceuticals Acquires 31 Generic Drug Products from Teva Pharmaceuticals

BAUDETTE, Minn., Dec. 26, 2013 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), an emerging generic pharmaceutical company, today announced that it has acquired 31 previously marketed generic drug products from Teva Pharmaceuticals for \$12.5 million in cash and a percentage of future gross profits from product sales. The acquisition includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products. ANI will begin work immediately on transferring these products into its manufacturing facilities in anticipation of product launches beginning in the fourth quarter of 2014. All of these products have been previously approved by FDA as abbreviated new drug

applications (ANDAs). The total current annual market for these products is \$860 million per IMS Health. Arthur S. Przybyl, President and CEO of ANI Pharmaceuticals, stated, "This acquisition is a significant opportunity for ANI to expand our generic product portfolio beyond our current seven marketed products. When launched, these products will strengthen our business by growing our revenue base and leveraging our manufacturing capabilities. We are excited that this transaction extends the ANI-Teva relationship beyond the existing generic testosterone gel partnership."

Robert W. Schrepfer, VP of New Business Development, commented, "This transaction demonstrates ANI's commitment to diversify our marketed product portfolio and supplement our internal product development efforts through a business development plan that includes partnerships, acquisitions and in-licensing."

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharma.com.

Filing Data

Not available.

Contract

Not available.